Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

@article{Smith2011FinalOS,
  title={Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial},
  author={I Quah Smith and J -Y. Pierga and Laura Biganzoli and Hern{\'a}n Cort{\'e}s-Fun{\'e}s and Christoph Thomssen and Silvana Saracchini and Bella Nisenbaum and Ignacio Pel{\'a}ez and Anja-Alexandra Duenne and Kathleen I. Pritchard},
  journal={Breast Cancer Research and Treatment},
  year={2011},
  volume={130},
  pages={133-143}
}
The ATHENA study expanded on the safety and efficacy data derived from first-line trials of bevacizumab combined with standard chemotherapy for locally recurrent/metastatic breast cancer (LR/mBC). In ATHENA, 2,264 patients received first-line bevacizumab-containing therapy in routine oncology practice. Overall survival (OS) data are now mature; additional analyses from this large data set can provide insights into treatment duration and the effect of prolonged bevacizumab exposure, where data… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS